Cargando…
Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma
BACKGROUND: Previous in vitro hepatocyte differentiation model showed that TROY was specifically expressed in liver progenitor cells and a small proportion of hepatocellular carcinoma cells, suggesting that TROY may participate in hepatocellular carcinoma (HCC) stemness regulation. Here, we aim to i...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131684/ https://www.ncbi.nlm.nih.gov/pubmed/35610614 http://dx.doi.org/10.1186/s13046-022-02401-6 |
_version_ | 1784713225396289536 |
---|---|
author | Liu, Beilei Fang, Xiaona Kwong, Dora Lai-Wan Zhang, Yu Verhoeft, Krista Gong, Lanqi Zhang, Baifeng Chen, Jie Yu, Qianqian Luo, Jie Tang, Ying Huang, Tuxiong Ling, Fei Fu, Li Yan, Qian Guan, Xin-Yuan |
author_facet | Liu, Beilei Fang, Xiaona Kwong, Dora Lai-Wan Zhang, Yu Verhoeft, Krista Gong, Lanqi Zhang, Baifeng Chen, Jie Yu, Qianqian Luo, Jie Tang, Ying Huang, Tuxiong Ling, Fei Fu, Li Yan, Qian Guan, Xin-Yuan |
author_sort | Liu, Beilei |
collection | PubMed |
description | BACKGROUND: Previous in vitro hepatocyte differentiation model showed that TROY was specifically expressed in liver progenitor cells and a small proportion of hepatocellular carcinoma cells, suggesting that TROY may participate in hepatocellular carcinoma (HCC) stemness regulation. Here, we aim to investigate the role and mechanism of TROY in HCC pathogenesis. METHOD: Bioinformatics analysis of the TCGA dataset has been used to identify the function and mechanism of TROY. Spheroid, apoptosis, and ALDH assay were performed to evaluate the stemness functions. Validation of the downstream pathway was based on Western blot, co-immunoprecipitation, and double immunofluorescence. RESULTS: HCC tissue microarray study found that a high frequency of TROY-positive cells was detected in 53/130 (40.8%) of HCC cases, which was significantly associated with poor prognosis and tumor metastasis. Functional studies revealed that TROY could promote self-renewal, drug resistance, tumorigenicity, and metastasis of HCC cells. Mechanism study found that TROY could interact with PI3K subunit p85α, inducing its polyubiquitylation and degradation. The degradation of p85α subsequently activate PI3K/AKT/TBX3 signaling and upregulated pluripotent genes expression including SOX2, NANOG, and OCT4, and promoted EMT in HCC cells. Interestingly, immune cell infiltration analysis found that upregulation of TROY in HCC tissues was induced by TGF-β1 secreted from CAFs. PI3K inhibitor wortmannin could effectively impair tumor stemness to sorafenib. CONCLUSION: We demonstrated that TROY is an HCC CSC marker and plays an important role in HCC stemness regulation. Targeting TROY-positive CSCs with PI3K inhibitor wortmannin combined with chemo- or targeted drugs might be a novel therapeutic strategy for HCC patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-022-02401-6. |
format | Online Article Text |
id | pubmed-9131684 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-91316842022-05-26 Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma Liu, Beilei Fang, Xiaona Kwong, Dora Lai-Wan Zhang, Yu Verhoeft, Krista Gong, Lanqi Zhang, Baifeng Chen, Jie Yu, Qianqian Luo, Jie Tang, Ying Huang, Tuxiong Ling, Fei Fu, Li Yan, Qian Guan, Xin-Yuan J Exp Clin Cancer Res Research BACKGROUND: Previous in vitro hepatocyte differentiation model showed that TROY was specifically expressed in liver progenitor cells and a small proportion of hepatocellular carcinoma cells, suggesting that TROY may participate in hepatocellular carcinoma (HCC) stemness regulation. Here, we aim to investigate the role and mechanism of TROY in HCC pathogenesis. METHOD: Bioinformatics analysis of the TCGA dataset has been used to identify the function and mechanism of TROY. Spheroid, apoptosis, and ALDH assay were performed to evaluate the stemness functions. Validation of the downstream pathway was based on Western blot, co-immunoprecipitation, and double immunofluorescence. RESULTS: HCC tissue microarray study found that a high frequency of TROY-positive cells was detected in 53/130 (40.8%) of HCC cases, which was significantly associated with poor prognosis and tumor metastasis. Functional studies revealed that TROY could promote self-renewal, drug resistance, tumorigenicity, and metastasis of HCC cells. Mechanism study found that TROY could interact with PI3K subunit p85α, inducing its polyubiquitylation and degradation. The degradation of p85α subsequently activate PI3K/AKT/TBX3 signaling and upregulated pluripotent genes expression including SOX2, NANOG, and OCT4, and promoted EMT in HCC cells. Interestingly, immune cell infiltration analysis found that upregulation of TROY in HCC tissues was induced by TGF-β1 secreted from CAFs. PI3K inhibitor wortmannin could effectively impair tumor stemness to sorafenib. CONCLUSION: We demonstrated that TROY is an HCC CSC marker and plays an important role in HCC stemness regulation. Targeting TROY-positive CSCs with PI3K inhibitor wortmannin combined with chemo- or targeted drugs might be a novel therapeutic strategy for HCC patients. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-022-02401-6. BioMed Central 2022-05-25 /pmc/articles/PMC9131684/ /pubmed/35610614 http://dx.doi.org/10.1186/s13046-022-02401-6 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Liu, Beilei Fang, Xiaona Kwong, Dora Lai-Wan Zhang, Yu Verhoeft, Krista Gong, Lanqi Zhang, Baifeng Chen, Jie Yu, Qianqian Luo, Jie Tang, Ying Huang, Tuxiong Ling, Fei Fu, Li Yan, Qian Guan, Xin-Yuan Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma |
title | Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma |
title_full | Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma |
title_fullStr | Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma |
title_full_unstemmed | Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma |
title_short | Targeting TROY-mediated P85a/AKT/TBX3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma |
title_sort | targeting troy-mediated p85a/akt/tbx3 signaling attenuates tumor stemness and elevates treatment response in hepatocellular carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131684/ https://www.ncbi.nlm.nih.gov/pubmed/35610614 http://dx.doi.org/10.1186/s13046-022-02401-6 |
work_keys_str_mv | AT liubeilei targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma AT fangxiaona targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma AT kwongdoralaiwan targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma AT zhangyu targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma AT verhoeftkrista targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma AT gonglanqi targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma AT zhangbaifeng targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma AT chenjie targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma AT yuqianqian targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma AT luojie targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma AT tangying targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma AT huangtuxiong targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma AT lingfei targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma AT fuli targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma AT yanqian targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma AT guanxinyuan targetingtroymediatedp85aakttbx3signalingattenuatestumorstemnessandelevatestreatmentresponseinhepatocellularcarcinoma |